



NDA 050592/S-051

**APPROVAL LETTER**

Sandoz Inc.  
Attention: Gregory Seitz  
Head US Regulatory Affairs  
100 College Road West  
Princeton, NJ 08540

Dear Gregory Seitz:

Please refer to your Supplemental New Drug Application (sNDA) dated and received October 30, 2024, and your amendment, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Tobradex (tobramycin and dexamethasone ophthalmic suspension).

This “Changes Being Effectuated in 30 days” supplemental new drug application provides for the addition of a (b) (4) on the secondary packaging component (carton) and removal of the (b) (4) (b) (4) (b) (4).

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

**CARTON LABELS**

Submit final printed carton labels that are identical to enclosed carton labels and carton labels submitted on December 26, 2024, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission **“Product Correspondence – Final Printed Carton and Container Labels for approved NDA 050592/S-051.”** Approval of this submission by FDA is not required before the labeling is used.

We remind you that you must comply with reporting requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

NDA 050592/S-051

Page 2

If you have any questions, please contact Shazma Aftab, PharmD, Regulatory Business Process Manager, at [shazma.aftab@fda.hhs.gov](mailto:shazma.aftab@fda.hhs.gov) or (301) 796 - 3138.

Sincerely,

*{See appended electronic signature page}*

David Lewis, PhD  
Supervisor  
Division of Product Quality Assessment XI  
Office of Product Quality Assessment II  
Office of Pharmaceutical Quality  
Center for Drug Evaluation and Research

Enclosure(s):  
Carton Labeling



David  
Lewis

Digitally signed by David Lewis

Date: 4/07/2025 02:08:02PM

GUID: 508da72000029f287fa31e664741b577